Synapse - Pamela Drullinsky

Results (91)

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study

Journal Article

Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
Lancet Oncology (2024)

Fulltext@MSK | Save

Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation

Journal Article

Epstein-Peterson, Z. D.; Drill, E.; Aypar, U.; Batlevi, C. L.; Caron, P.; Dogan, A.; Drullinsky, P.; Gerecitano, J.; Hamlin, P. A.; Ho, C.; more...
Haematologica (2024)

Fulltext@MSK | Save

Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study

Journal Article

Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
Lancet (2024)

Fulltext@MSK | Save

Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma

Journal Article

Grieve, C.; Joseph, A.; Drullinsky, P.; Zelenetz, A. D.; Hamlin, P.; Kumar, A.
Leukemia and Lymphoma (2024)

Fulltext@MSK | Save

Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study

Meeting Abstract

Chia, S.; Neven, P.; Ciruelos, E. M.; Lerebours, F.; Ruiz-Borrego, M.; Drullinsky, P.; Prat, A.; Park, Y. H.; Juric, D.; Turner, N. C.; more...
Journal of Clinical Oncology (2023)

Fulltext@MSK | Save

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2

Meeting Abstract

Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
Blood (2022)

Fulltext@MSK | Save

Bendamustine in combination with ofatumumab as first line treatment for elderly patients with mantle cell lymphoma: A phase II risk-adapted design

Journal Article

Kumar, A.; Casulo, C.; Joffe, E.; Moskowitz, C.; Gerecitano, J.; Moskowitz, A.; Younes, A.; Drullinsky, P.; Drill, E.; Choma, M.; more...
Leukemia and Lymphoma (2022)

Fulltext@MSK | Save

Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study

Meeting Abstract

Dejan, J.; Rugo, H. S.; Chia, S. K. L.; Lerebours, F.; Ruiz-Borrego, M.; Drullinsky, P.; Ciruelos, E. M.; Neven, P.; Park, Y. H.; Arce, C. H.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers